SCHEMBL1095058

SCHEMBL1095058

Cc1nsc(NS(=O)(=O)c2ccccc2F)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 2/20 0.49
POLB P06746 1/20 0.49
EDNRA P25101 2/20 0.49
EDNRB P24530 1/20 0.47
ALDH1A1 P00352 1/20 0.46
KDM4E B2RXH2 2/20 0.44
MEN1 O00255 1/20 0.44
LMNA P02545 1/20 0.44
HPGD P15428 1/20 0.44
HTT P42858 1/20 0.44
KMT2A Q03164 1/20 0.44
SCN9A Q15858 6/20 0.43
SCN2B O60939 1/20 0.43
SCN1B Q07699 1/20 0.43
TSHR P16473 1/20 0.42
GCK P35557 1/20 0.41
PTPN2 P17706 1/20 0.41
PTPN1 P18031 1/20 0.41
PTPN5 P54829 1/20 0.41
NPC1 O15118 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17048667 0.81 SCN9A (0.50) SCN9ASCN2BSCN1B
SCHEMBL3475966 0.79 ALDH1A1 (0.54) PKMALDH1A1KDM4EMEN1LMNA
SCHEMBL5401636 0.78 HSD11B1 (0.58) EDNRAEDNRBHTTSCN9A
SCHEMBL1094211 0.75 ALDH1A1 (0.54) PKMPOLBEDNRAEDNRBALDH1A1
SCHEMBL1094819 0.75 L3MBTL1 (0.55) POLBALDH1A1KMT2ASCN9APTPN2
SCHEMBL1094585 0.74 SCN9A (0.55) SCN9ASCN2BSCN1B
SCHEMBL712379 0.73 GAA (0.47) POLBALDH1A1KDM4ELMNAHPGD
SCHEMBL5391658 0.73 MAPT (0.56) ALDH1A1MEN1HPGDHTTKMT2A
SCHEMBL5401916 0.71 CA1 (0.53) POLBALDH1A1KDM4EMEN1LMNA
SCHEMBL5402279 0.71 LMNA (0.57) ALDH1A1KDM4EMEN1LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8907101-B2 Sulfonamide derivatives PFIZER LIMITED (GB) 2014-12-09 US disclosed
US-20130338111-A1 Sulfonamide Derivatives ICAGEN, INC. (US) 2013-12-19 US disclosed
US-20120149679-A1 Sulfonamide Derivatives ICAGEN, INC. 2012-06-14 US disclosed
US-8153814-B2 Sulfonamide derivatives PFIZER LIMITED (GB) 2012-04-10 US disclosed
US-20100197655-A1 SULFONAMIDE DERIVATIVES Pfizer Limited Icagen, Inc. 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197655-A1 SULFONAMIDE DERIVATIVES SULT2A1, SULT1A1, TPST2 PKM 367/4885POLB 3499/4885EDNRA 3990/4885
US-20130338111-A1 Sulfonamide Derivatives SULT2A1, SULT1A1, TPST2 PKM 367/4885POLB 3499/4885EDNRA 3990/4885
US-20120149679-A1 Sulfonamide Derivatives SULT2A1, SULT1A1, TPST2 PKM 367/4885POLB 3499/4885EDNRA 3990/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.